Modeling Neurodegenerative Disorders: Where Are We Now?

Approved therapies for Alzheimer's, Parkinson's, ALS, and related diseases manage symptoms but leave disease progression largely untouched. Closing that gap requires preclinical models that more faithfully capture the complexity of human neurodegeneration, including region-specific neuronal loss, diverse cell-type involvement, and the slow, progressive nature of these conditions. As global populations age, the stakes for getting this right are rising.

This article reviews the current state of modeling approaches, where they succeed, and where they fall short in reproducing the biology that matters most for drug development. Read it to sharpen your perspective on which model systems are best positioned to support the next generation of neurodegeneration research.